NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
10/03/2019
Back to search
Official data from USPTO
INDUS PHARMACEUTICALS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
INDUS PHARMACEUTICALS
ST13
US500000078596173Class
42
Filing
78596173
Registration
3674488
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
50
Latest update
10/03/2019
Trademark type
Word
Nice classes
42
Filing date
03/28/2005
Registration date
08/25/2009
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/03/2019
Last transaction
10/03/2019
Responsible office
United States Patent and Trademark Office
Status code
800
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
03/31/2006
First use in commerce
03/31/2006
Drawing code
4
Owner type
03
Owner location
Andover, MA, US
Examiner
BHANOT, KAPIL KUMAR
Law office
L80
Current location
GENERIC WEB UPDATE
Holders and representatives
Holders
IndUS Pharmaceuticals, Inc.
Representatives
H. Straat Tenney Locke Lord LLP
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
pharmaceutical drug development services of pharmaceutical products intended for the treatment of infectious diseasesbacterialfungalparasitic and viral infections; pharmaceutical drug development services of pharmaceutical products intended for the treatment of neoplastic disordershematologic cancer disorders and solid tumors; pharmaceutical drug development services of pharmaceutical products intended for the treatment of autoimmune disordersdiabetesarthritispsoriasisbone marrow and organ transplantation and immunosuppression; pharmaceutical drug development services of pharmaceutical products intended for the treatment of metabolic disordersobesity and atherosclerosis; pharmaceutical drug development services of pharmaceutical products intended for the treatment of cardiovascular disordershypertensioncongestive heart failuremyocardial infarctionangina and vascular diseases; pharmaceutical drug development services of pharmaceutical products intended for the treatment of renal disordersacute and chronic renal failure and urinary disorders affecting renal conservation of water; pharmaceutical drug development services of pharmaceutical products intended for the treatment of central nervous system disordersanalgesiaanesthesiahypnoticssedativesanxietypsychosisdepressionmaniaepilepsiesmigraineneurodegenerationdrug addiction; pharmaceutical drug development services of pharmaceutical products intended for the treatment of inflammatory disordersasthmagoutinflammatory bowel diseaserheumatoid arthritis; pharmaceutical drug development services of pharmaceutical products intended for the treatment of gastrointestinal disordersulcersemesisdiarrheairritable bowel syndrome; pharmaceutical drug development services of pharmaceutical products intended for the treatment of hormonal disorders affecting the thyroidestrogensprogestinsandrogensglucocorticoidsinsulin and glucose regulation; pharmaceutical drug development services of pharmaceutical products intended for the treatment of calcification and bone turnover; and pharmaceutical drug development services of pharmaceutical products intended for the treatment of dermatological and opthalmological disorders
Publications
History of USPTO decisions and trademark events.
50 publications found
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
10/03/2019
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
10/03/2019
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
10/03/2019
E89R
TEAS SECTION 8 & 9 RECEIVED
08/23/2019
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
08/25/2018
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
01/22/2016
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
09/25/2015
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
09/25/2015
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
09/25/2015
E815
TEAS SECTION 8 & 15 RECEIVED
08/21/2015
R.PR
REGISTERED-PRINCIPAL REGISTER
08/25/2009
REGV
LAW OFFICE REGISTRATION REVIEW COMPLETED
07/21/2009
ALIE
ASSIGNED TO LIE
07/21/2009
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
07/13/2009
SUPC
STATEMENT OF USE PROCESSING COMPLETE
07/09/2009
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
07/09/2009
EISU
TEAS STATEMENT OF USE RECEIVED
06/15/2009
IUAF
USE AMENDMENT FILED
06/13/2009
EX5G
SOU EXTENSION 5 GRANTED
12/10/2008
EXT5
SOU EXTENSION 5 FILED
12/10/2008
EEXT
SOU TEAS EXTENSION RECEIVED
12/10/2008
EX4G
SOU EXTENSION 4 GRANTED
06/12/2008
EXT4
SOU EXTENSION 4 FILED
06/12/2008
EEXT
SOU TEAS EXTENSION RECEIVED
06/12/2008
DOCK
ASSIGNED TO EXAMINER
01/08/2008
EX3G
SOU EXTENSION 3 GRANTED
12/13/2007
EXT3
SOU EXTENSION 3 FILED
12/13/2007
EEXT
SOU TEAS EXTENSION RECEIVED
12/13/2007
EX2G
SOU EXTENSION 2 GRANTED
06/13/2007
EXT2
SOU EXTENSION 2 FILED
06/13/2007
EEXT
SOU TEAS EXTENSION RECEIVED
06/13/2007
EX1G
SOU EXTENSION 1 GRANTED
12/13/2006
EXT1
SOU EXTENSION 1 FILED
12/13/2006
EEXT
SOU TEAS EXTENSION RECEIVED
12/13/2006
NOAM
NOA MAILED - SOU REQUIRED FROM APPLICANT
06/13/2006
PUBO
PUBLISHED FOR OPPOSITION
03/21/2006
NPUB
NOTICE OF PUBLICATION
03/01/2006
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
02/03/2006
ALIE
ASSIGNED TO LIE
12/02/2005
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/29/2005
GNEA
EXAMINERS AMENDMENT E-MAILED
11/29/2005
CNEA
EXAMINERS AMENDMENT -WRITTEN
11/29/2005
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/23/2005
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/17/2005
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/17/2005
GEAP
EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
10/25/2005
CPEA
EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED
10/25/2005
DOCK
ASSIGNED TO EXAMINER
10/22/2005
NWAP
NEW APPLICATION ENTERED
04/01/2005
Continuous trademark protection
Get notified about every new filing that threatens INDUS PHARMACEUTICALS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.